High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1459-1467

  Gervois, Nadine ^a   Labarriere, Nathalie ^a   Le Guiner, Soizic ^a   Pandolfino, Marie Christine ^b   Fonteneau, Jean François ^a   Guilloux, Yannik ^a   Diez, Elisabeth ^a   Dreno, Brigitte ^b   Jotereau, Francine ^a,c  

^a INSTITUT DE BIOLOGIE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MELANOMA CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CELL DIVISION; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LYMPHOCYTES; MELANOMA; NEOPLASM PROTEINS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0034006540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Van den Eynde, B. J., and Van der Bruggen, P. T. Cell-defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. Rosenberg, S, A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Imunol. Today, 18: 175-182, 1997.
3. Rouse, B. T., Wagner, H., and Harris, A. W. In vivo activity of in vitro immunized lymphocytes. I. Tumor allograft rejection mediated by in vitro activated mouse thymocytes. J. Immunol., 108: 1353-1361, 1972.
4. Melief, C. J. M., and Kast, W. M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev., 145: 167-177, 1995.
5. Alexander-Miller, M. A., Leggatt, G. R., and Berzofsky, J. A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA, 93: 4102-4107, 1996.
6. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. N., Mc Kall-Faienza, K., Odermatt, B., Hanahan, D., Zingernagel, R. M., and Ohashi, P. S. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med., 186: 645-653, 1997.
7. Nagoshi, M., Goedegebuure, P. S., Burger, U. L., Sadanaga, N., Chang, M. P., and Eberlein, T. J. Successful adoptive immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J. Immunol., 160: 334-344, 1998.
8. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., and Greenberg, P. D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (Washington DC), 257: 238-241, 1992.
9. Heslop, H. E., Ng, C. Y., Li, C., Smith, C. A., Loftin, S. K., Krance, R. A., Brenner, M. K., and Rooney, C. M. Long-term restoration of immunity against Epstein-Barr vims infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med., 2: 551-555, 1996.
10. Boon, T., and Old, L. J. Cancer tumor antigens. Curr. Opin. Immunol., 9: 681-683, 1997.
11. Celis, E., Tsai, V., Crimi, C, DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., and Serra, H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA. 91: 2105-2109, 1994.
12. Van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De Smet, C., Traversari, C., Townsend, A., and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24: 3038-3043, 1994.
13. Visseren, M. J. W., van Elsas, A., van der Voort, E. I. H., Ressing, M. E., Kast, W. M., Schrier, P. I., and Melief, C. J. M. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol., 154: 3991-3998, 1995.
14. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Scouthwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
15. Tsai, V., Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., and Cells, E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158: 1796-1802, 1997.
16. Gervois, N., Guilloux, Y., Diez, E., and Jotereau, F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med., 183: 2403-2407, 1996.
17. Dunbar, P. R., Chen, J. L., Chao, D., Rust, N., Teisserenc, H., Ogg, G. S., Romero, P., Weynants, P., and Cerundolo, V. Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J. Immunol., 162: 6959-6962, 1999.
18. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., and Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol., 162: 2227-2234, 1999.
19. Fonteneau, J. F., Le Drean, E., Le Guiner, S., Gervois, N., Diez, E., and Jotereau, F. Heterogeneity of biologic responses of melanoma-specific CTL. J. Immunol., 159: 2831-2839, 1997.
20. Valitutti, S., Muller, S., Dessing, M., and Lanzavecchia, A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med., 183: 1917-1921, 1996.
21. Gervois, N., Heuzé, F., Diez, E, and Jotereau, F. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in a bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur. J. Immunol., 20: 825-831, 1990.
22. Jung, T., Schauer, U., Heusser, C., Neumann, C., and Rieger, C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods, 159: 197-207, 1993.
23. Jotereau, F., Pandolfino, M. C., Boudart, D., Diez, E., Dreno, B., Douillard, J. Y., Muller, J. Y., and Le Mevel, B. High fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J. Immunother., 10: 405-411, 1991.
24. Labarrière, N., Diez, E., Pandolfino, M. C., Viret, C., Guilloux, Y., Le Guiner, S., Fonteneau, J. F., Dreno, B., and Jotereau, F. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J. Immunol., 158: 1238-1245, 1997.
25. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi; D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
26. Tessier, M. H., Pandolfino, M. C., Jotereau, F., Boudart, D., Litoux, P., and Dreno, B. Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma. Eur. J. Cancer, 4: 735-736, 1996.
27. Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Lienard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, and Dreno, B. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med., 190: 705-715, 1999.
28. Ostankovitch, M., Le Gal, F. A., Connan, F., Chassin, D., Choppin, J., and Guillet, J. G. Generation of MelanA/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro. Int. J. Cancer, 72: 987-994, 1997.
29. Alexander-Miller, M. A., Derby, M. A., Sarin, A., Henkart, P. A., and Berzofsky, J. A. Supraoptimal peptide-major histocornpatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor a receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med., 188: 1391-1399, 1998.
30. Le Guiner, S., Le Drean; E., Labarriere, N., Fonteneau, J. F., Viret, C., Diez, E., and Jotereau, F. LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal. Eur. J. Immunol., 28: 1322-1331, 1998.
31. Harding, F. A., Mc Arthur, J. G., Gross, J. A., Raulet, D. H., and Allison, J. P. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (Lond.), 356: 607-609, 1992.
32. Green, J. M., Noel, P. J., Sperling, A. I., Walunas, T. L., Gray, G. S., Bluestone, J. A., and Thompson, C. B. Absence of B7-dependent responses in CD28-deficient mice. Immunity, 1: 501-508, 1994.
33. Cai, Z., and Sprent, J. Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J. Exp. Med., 183: 2247-2257, 1996.
34. Bakker, A. B., Marland, G., de Boer, A. J., Huijbens, R. J., Danen, E. H., Adema, G. J., and Figdor, C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55: 5330-5334, 1995.
35. Mehta-Damani, A., Markowicz, S., and Engleman, E. G. Generation of antigen-specific CD8+ CTLs from naive precursors. J. Immunol., 153: 996-1003, 1994.
36. Stevens, E. J., Jacknin, L., Robbins, P. F., Kawakami, Y., El Gamil, M., Rosenberg, S. A., and Yannelin, J. R. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J. Immunol., 154: 762-777, 1995.